These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38348830)

  • 1. Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.
    Dubé K; Ndukwe SO; Korolkova A; Dee L; Sugarman J; Sauceda JA
    HIV Res Clin Pract; 2024 Jan; 25(1):2312318. PubMed ID: 38348830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.
    Bilger A; Plenn E; Barg FK; Rendle KA; Carter WB; Lamour-Harrington A; Jones N; Peterson B; Sauceda JA; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dubé K
    HIV Res Clin Pract; 2023 Oct; 24(1):2267825. PubMed ID: 37837376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption.
    Neergaard R; Jones NL; Roebuck C; Rendle KA; Barbati Z; Peterson B; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dube K; Barg FK
    AIDS Res Hum Retroviruses; 2023 Aug; 39(8):414-421. PubMed ID: 35979886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States.
    Campbell DM; Dubé K; Cowlings PD; Dionicio P; Tam RM; Agarwal H; Stockman JK; Auerbach JD; Sauceda JA; Conroy AA; Johnson MO
    BMC Public Health; 2022 Jul; 22(1):1317. PubMed ID: 35810288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom.
    Lee MJ; Godakandaarachchi P; Collins S; Racz M; Sharp A; Fidler S; Fox J
    J Virus Erad; 2023 Dec; 9(4):100360. PubMed ID: 38188642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis.
    Lee MJ; Eason M; Castagna A; Laura G; De Scheerder MA; Riley J; Tebas P; Gunst J; Søgaard O; Florence E; Kroon E; De Souza M; Mothe B; Caskey M; Fidler S
    J Int AIDS Soc; 2024 Aug; 27(8):e26349. PubMed ID: 39155436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.
    Dubé K; Kanazawa J; Campbell C; Boone CA; Maragh-Bass AC; Campbell DM; Agosto-Rosario M; Stockman JK; Diallo DD; Poteat T; Johnson M; Saberi P; Sauceda JA
    AIDS Res Hum Retroviruses; 2022 Jan; 38(1):50-63. PubMed ID: 33947268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptions.
    Dubé K; Agarwal H; Carter WB; Dee L; Taylor J; Roebuck C; Peterson B; Patel H; Ndukwe S; Lynn KM; Lalley-Chareczko L; Hiserodt E; Kim S; Rosenbloom D; Evans BR; Anderson M; Hazuda DJ; Bateman K; Howell BJ; Azzoni L; Mounzer K; Tebas P; Montaner LJ
    HIV Res Clin Pract; 2022 Aug; 23(1):76-90. PubMed ID: 35968737
    [No Abstract]   [Full Text] [Related]  

  • 9. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.
    Dubé K; Kanazawa J; Dee L; Taylor J; Campbell DM; Brown B; Johnson MO; Saberi P; Sauceda JA; Sugarman J; Peluso MJ
    HIV Res Clin Pract; 2021 Feb; 22(1):14-30. PubMed ID: 33757411
    [No Abstract]   [Full Text] [Related]  

  • 10. Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies.
    Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):260-267. PubMed ID: 31608648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motivations, barriers and experiences of participants in an HIV reservoir trial.
    De Scheerder MA; van Bilsen WPH; Dullaers M; Martinez-Picado J; Davidovich U; Vandekerckhove L
    J Virus Erad; 2021 Mar; 7(1):100029. PubMed ID: 33598311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
    Lee MJ; Collins S; Babalis D; Johnson N; Falaschetti E; Prevost AT; Ashraf A; Jacob M; Cole T; Hurley L; Pace M; Ogbe A; Khan M; Zacharopoulou P; Brown H; Sutherland E; Box H; Fox J; Deeks S; Horowitz J; Nussenzweig MC; Caskey M; Frater J; Fidler S
    Trials; 2022 Apr; 23(1):263. PubMed ID: 35382844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.
    Okumu EA; Henderson GE; Golin C; Kuczynski K; Ormsby NQ; Peay HL
    J Virus Erad; 2023 Jun; 9(2):100331. PubMed ID: 37416088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A partner protection package for HIV cure-related trials involving analytical treatment interruptions.
    Dubé K; Morton T; Fox L; Dee L; Palm D; Villa TJ; Freshwater W; Taylor J; Graham G; Carter WB; Sauceda JA; Peluso MJ; Rid A
    Lancet Infect Dis; 2023 Oct; 23(10):e418-e430. PubMed ID: 37295453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.
    Hellmuth J; Muccini C; Colby DJ; Kroon E; de Souza M; Crowell TA; Chan P; Sacdalan C; Intasan J; Benjapornpong K; Tipsuk S; Puttamaswin S; Chomchey N; Valcour V; Sarnecki M; Tomaka F; Krebs SJ; Slike BM; Jagodzinski LL; Dumrongpisutikul N; Sailasuta N; Samboju V; Michael NL; Robb ML; Vasan S; Ananworanich J; Phanuphak P; Phanuphak N; Paul R; Spudich S
    Clin Infect Dis; 2021 Oct; 73(7):e1885-e1892. PubMed ID: 32916708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection.
    van Paassen P; Dijkstra M; Peay HL; Rokx C; Verbon A; Reiss P; Prins JM; Henderson GE; Rennie S; Nieuwkerk PT; de Bree GJ
    J Virus Erad; 2022 Jun; 8(2):100072. PubMed ID: 35769632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recall and Appraisal of the Risks, Benefits, and Objectives of Interrupting HIV Treatment in an HIV Cure-Related Study.
    Korolkova A; Ndukwe SO; Dee L; Deeks SG; Peluso MJ; Hoh R; Rodriguez A; Sugarman J; Rodriguez Garcia L; Dubé K; Sauceda JA
    AIDS Behav; 2024 Dec; 28(12):4136-4145. PubMed ID: 39287733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'With this study, we have hope that something is coming': community members' perceptions of HIV cure-related research in Durban, South Africa - a qualitative focus group study.
    Dubé K; Mthimkhulu D; Ngcobo W; Mindry D; Maphalala L; Pillay V; Tran W; Korolkova A; Ndung'u T; Dong K
    HIV Res Clin Pract; 2023 Jul; 24(1):2243046. PubMed ID: 37555592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk.
    Dubé K; Villa TJ; Freshwater W; Mauk B; Rid A; Peluso MJ
    J Virus Erad; 2024 Sep; 10(3):100386. PubMed ID: 39364082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.
    De Scheerder MA; Van Hecke C; Zetterberg H; Fuchs D; De Langhe N; Rutsaert S; Vrancken B; Trypsteen W; Noppe Y; Van Der Gucht B; Pelgrom J; Van Wanzeele F; Palmer S; Lemey P; Gisslén M; Vandekerckhove L
    J Antimicrob Chemother; 2020 May; 75(5):1311-1320. PubMed ID: 32053203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.